NHAS
VRDN icon

Novo Holdings A/S’s Viridian Therapeutics VRDN Stock Holding History

Novo Holdings A/S’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.1M Sell
2,000,000
-380,000
-16% -$11.3M 3.17% 12
2025
Q4 		$74.1M Hold
2,380,000
– – 5.75% 7
2025
Q3 		$51.4M Hold
2,380,000
– – 3.31% 9
2025
Q2 		$33.3M Buy
2,380,000
+129,700
+6% +$1.76M 2.35% 15
2025
Q1 		$30.3M Buy
2,250,300
+300
+0% +$5.11K 2.31% 15
2024
Q4 		$43.1M Sell
2,250,000
-135,000
-6% -$2.94M 2.61% 12
2024
Q3 		$54.3M Buy
2,385,000
+385,000
+19% +$6.29M 2.69% 10
2024
Q2 		$26M Buy
2,000,000
+900,000
+82% +$12.5M 1.4% 23
2024
Q1 		$19.3M Buy
+1,100,000
New +$21.3M 1.33% 24

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return